Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NADEGE T GUNN

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1902822281
CMS profile
267222
Location
WACO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$487,497.14

353 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 6 of 8; records 251–300 of 353 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NADEGE T GUNN

NPI 1902822281 · CMS profile ID 267222

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

WACO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 6 of 8; records 251–300 of 353 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1902822281?year=2025&recipient=provider&page=6#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NADEGE T GUNN, NPI 1902822281, CMS profile ID 267222. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 8; records 251–300 of 353 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1902822281?year=2025&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). NADEGE T GUNN, NPI 1902822281, CMS profile ID 267222. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 8; records 251–300 of 353 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1902822281?year=2025&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
NADEGE T GUNN, NPI 1902822281, CMS profile ID 267222, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 8; records 251–300 of 353 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1902822281?year=2025&recipient=provider&page=6#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

353 matching records · $487,497.14 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 353 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 251–300 of 353.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $632.5804/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1222985309 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $310.6004/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1222985311 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $292.6004/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1222985313 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $254.0404/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1222985315 CMS
Madrigal Pharmaceuticals $42.5304/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248265998 CMS
Madrigal Pharmaceuticals $108.0004/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248266000 CMS
Madrigal Pharmaceuticals $13.0704/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248266002 CMS
Madrigal Pharmaceuticals $36.7204/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248266004 CMS
Madrigal Pharmaceuticals $10.4004/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248266006 CMS
Madrigal Pharmaceuticals $67.5004/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248266008 CMS
Madrigal Pharmaceuticals $7,050.0004/11/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1248265984 CMS
Madrigal Pharmaceuticals $627.9604/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1248265986 CMS
Madrigal Pharmaceuticals $302.5604/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1248265988 CMS
Madrigal Pharmaceuticals $216.8504/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1248265990 CMS
Madrigal Pharmaceuticals $225.7404/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248265992 CMS
Madrigal Pharmaceuticals $8.3104/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248265994 CMS
Madrigal Pharmaceuticals $124.1604/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1248265996 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $106.5204/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231971829 CMS
Gilead Sciences, Inc. $4,065.0004/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234354285 CMS
Gilead Sciences, Inc. $18.6404/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234542885 CMS
Madrigal Pharmaceuticals $9.7704/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248265982 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $361.4404/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1222985345 CMS
Gilead Sciences, Inc. $11.5604/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234583908 CMS
Gilead Sciences, Inc. $3,790.0003/31/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234354555 CMS
Boehringer Ingelheim International GmbH $7,350.0003/27/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1215872911 CMS
Boehringer Ingelheim International GmbH $1,600.0003/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1215872916 CMS
Boehringer Ingelheim International GmbH $125.3003/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1215872924 CMS
Gilead Sciences, Inc. $9.9003/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234586854 CMS
Novo Nordisk Inc $24.5803/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189166927 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $2,940.0003/25/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1222985363 CMS
Gilead Sciences, Inc. $108.0303/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234399015 CMS
Gilead Sciences, Inc. $75.1003/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234408517 CMS
Madrigal Pharmaceuticals $28.1503/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248265980 CMS
Gilead Sciences, Inc. $24.0003/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234373899 CMS
Gilead Sciences, Inc. $33.7203/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234421220 CMS
Gilead Sciences, Inc. $3.2903/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234607001 CMS
Madrigal Pharmaceuticals $163.5603/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248265978 CMS
Madrigal Pharmaceuticals $142.9103/19/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1248265968 CMS
Madrigal Pharmaceuticals $87.4203/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248265970 CMS
Madrigal Pharmaceuticals $47.3903/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248265972 CMS
Madrigal Pharmaceuticals $4,230.0003/19/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1248265974 CMS
Madrigal Pharmaceuticals $17.0303/19/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1248265976 CMS
Ipsen Biopharmaceuticals, Inc $32.2503/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208843405 CMS
Gilead Sciences, Inc. $6,190.0003/13/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234353477 CMS
Madrigal Pharmaceuticals $6,772.5003/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1248265960 CMS
Madrigal Pharmaceuticals $3,870.0003/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1248265962 CMS
Madrigal Pharmaceuticals $172.2803/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1248265964 CMS
Madrigal Pharmaceuticals $201.1403/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1248265966 CMS
Madrigal Pharmaceuticals $1,290.0003/10/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1248265958 CMS
Boehringer Ingelheim International GmbH $612.6803/07/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1215872928 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $64,813.39 172
PY2020 $23,268.77 62
PY2021 $34,340.02 50
PY2022 $51,451.67 83
PY2023 $63,385.59 119
PY2024 $208,333.35 250
PY2025 $487,497.14 353

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,235,295.76 387
PY2024 Recipient $19.05 1
PY2024 Principal investigator $864,482.52 85
PY2023 Recipient $1,761.83 2
PY2023 Principal investigator $570,518.92 29
PY2022 Recipient $577.01 3
PY2022 Principal investigator $158,872.78 17
PY2021 Recipient $2,757.60 1
PY2021 Principal investigator $190,613.34 24
PY2020 Principal investigator $531,012.75 21
PY2019 Recipient $144.86 2
PY2019 Principal investigator $1,223,702.45 69

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

387 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 12/31/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729307
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 12/31/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729309
Principal investigator 1 Boehringer Ingelheim International GmbH $163.24 12/17/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220728983
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 12/17/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220728985
Principal investigator 1 Boehringer Ingelheim International GmbH $693.50 12/17/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220728987
Principal investigator 1 Boehringer Ingelheim International GmbH $6.00 12/17/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220728989
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 12/17/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770559
Principal investigator 1 Boehringer Ingelheim International GmbH $800.00 12/10/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220728971
Principal investigator 1 Boehringer Ingelheim International GmbH $800.00 12/10/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220728973
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,612.00 12/08/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808244
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $400.00 12/02/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220800860
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728825
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728827
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728829
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728831
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728833
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728835
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729295
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729297
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770557
Principal investigator 1 Boehringer Ingelheim International GmbH $2,143.38 11/27/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728911
Principal investigator 1 Boehringer Ingelheim International GmbH $2,143.38 11/27/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728913
Principal investigator 1 Boehringer Ingelheim International GmbH $2,913.44 11/27/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728915
Principal investigator 1 Boehringer Ingelheim International GmbH $2,511.73 11/27/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728917
Principal investigator 1 Boehringer Ingelheim International GmbH $770.06 11/27/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728919
Principal investigator 1 Boehringer Ingelheim International GmbH $770.06 11/27/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220728969
Principal investigator 1 Boehringer Ingelheim International GmbH $2,608.00 11/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729281
Principal investigator 1 Boehringer Ingelheim International GmbH $2,608.00 11/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729283
Principal investigator 1 Boehringer Ingelheim International GmbH $2,608.00 11/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729285
Principal investigator 1 Boehringer Ingelheim International GmbH $3,796.00 11/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729287
Principal investigator 1 Boehringer Ingelheim International GmbH $2,018.00 11/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729289
Principal investigator 1 Boehringer Ingelheim International GmbH $16,986.00 11/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729291
Principal investigator 1 Boehringer Ingelheim International GmbH $16,986.00 11/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729293
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 11/19/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728925
Principal investigator 1 Boehringer Ingelheim International GmbH $255.50 11/19/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728927
Principal investigator 1 Boehringer Ingelheim International GmbH $4.20 11/19/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728929
Principal investigator 1 Boehringer Ingelheim International GmbH $5.00 11/19/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728931
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 11/19/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220728979
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 11/19/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220728981
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,073.00 11/13/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808242
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 11/07/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808240
Principal investigator 1 Genentech, Inc. $14,500.00 11/07/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with T2DM No dispute reported 06/30/2026 1211682274
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728813
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728815
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728817
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728819
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728821
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728823
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729277
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729279
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770555
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 10/31/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729299
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 10/31/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729301
Principal investigator 1 Genentech, Inc. $63,662.00 10/29/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211682252
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 10/28/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729303
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 10/28/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729305
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 10/27/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728837
Principal investigator 1 Boehringer Ingelheim International GmbH $1.74 10/27/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728839
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 10/27/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728921
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 10/27/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728923
Principal investigator 1 Boehringer Ingelheim International GmbH $2,250.41 10/27/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220728967
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 10/27/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220728975
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 10/27/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220728977
Principal investigator 1 Genentech, Inc. $2,751.00 10/23/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211682242
Principal investigator 1 Genentech, Inc. $13,558.00 10/09/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity No dispute reported 06/30/2026 1211682240
Principal investigator 1 Boehringer Ingelheim International GmbH $1,016.00 10/02/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729271
Principal investigator 1 Boehringer Ingelheim International GmbH $11,200.00 10/02/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729273
Principal investigator 1 Boehringer Ingelheim International GmbH $20,150.00 10/02/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729275
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728801
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728803
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728805
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728807
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728809
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728811
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729267
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729269
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 10/01/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770549
Principal investigator 1 Boehringer Ingelheim International GmbH $129.00 10/01/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770551
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770553
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 09/30/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729247
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 09/30/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729249
Principal investigator 1 Bausch Health US, LLC $3,524.92 09/24/2025 Non-covered Recipient Entity
IMPACT RESEARCH INSTITUTE 54723
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224841876
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 09/24/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728797
Principal investigator 1 Boehringer Ingelheim International GmbH $12.18 09/24/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728799
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,267.30 09/18/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808238
Principal investigator 1 Boehringer Ingelheim International GmbH $382.00 09/17/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729233
Principal investigator 1 Boehringer Ingelheim International GmbH $400.00 09/17/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729235
Principal investigator 1 Boehringer Ingelheim International GmbH $418.00 09/17/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729237
Principal investigator 1 Boehringer Ingelheim International GmbH $47.00 09/17/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729239
Principal investigator 1 Boehringer Ingelheim International GmbH $139.00 09/17/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729245
Principal investigator 1 Boehringer Ingelheim International GmbH $687.00 09/17/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729255
Principal investigator 1 Madrigal Pharmaceuticals $2,644.52 09/12/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250021
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,500.00 09/11/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220800858
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728765
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728767
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728769
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728771
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728773
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728791
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729209
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729211
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770547
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 08/29/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729241
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 08/29/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729243
Principal investigator 1 Boehringer Ingelheim International GmbH $3,500.02 08/28/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728873
Principal investigator 1 Boehringer Ingelheim International GmbH $770.06 08/28/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728885
Principal investigator 1 Boehringer Ingelheim International GmbH $22,109.34 08/28/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728889
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 08/26/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220728965
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 08/26/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729259
Principal investigator 1 Boehringer Ingelheim International GmbH $366.42 08/26/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729261
Principal investigator 1 Boehringer Ingelheim International GmbH $9.72 08/26/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729263
Principal investigator 1 Boehringer Ingelheim International GmbH $35.04 08/26/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729265
Principal investigator 1 Boehringer Ingelheim International GmbH $229.00 08/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729217
Principal investigator 1 Boehringer Ingelheim International GmbH $313.00 08/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729227
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729229
Principal investigator 1 Madrigal Pharmaceuticals $4,897.40 08/21/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248971
Principal investigator 1 Boehringer Ingelheim International GmbH $417.00 08/18/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729219
Principal investigator 1 Boehringer Ingelheim International GmbH $418.00 08/18/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729221
Principal investigator 1 Boehringer Ingelheim International GmbH $47.00 08/18/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729223
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 08/18/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729225
Principal investigator 1 Boehringer Ingelheim International GmbH $229.00 08/18/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729231
Principal investigator 1 Bausch Health US, LLC $9,134.12 08/08/2025 Non-covered Recipient Entity
IMPACT RESEARCH INSTITUTE 54723
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224841872
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $30,769.20 08/06/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808236
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 08/05/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220998435
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728755
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728757
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728759
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728761
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728763
Principal investigator 1 Boehringer Ingelheim International GmbH $30.79 08/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728785
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728789
Principal investigator 1 Boehringer Ingelheim International GmbH $48.65 08/01/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728875
Principal investigator 1 Boehringer Ingelheim International GmbH $375.00 08/01/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728877
Principal investigator 1 Boehringer Ingelheim International GmbH $400.00 08/01/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728879
Principal investigator 1 Boehringer Ingelheim International GmbH $61.16 08/01/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728881
Principal investigator 1 Boehringer Ingelheim International GmbH $806.20 08/01/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728883
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 08/01/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728887
Principal investigator 1 Boehringer Ingelheim International GmbH $48.65 08/01/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728891
Principal investigator 1 Boehringer Ingelheim International GmbH $243.25 08/01/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728893
Principal investigator 1 Boehringer Ingelheim International GmbH $125.10 08/01/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728895
Principal investigator 1 Boehringer Ingelheim International GmbH $278.00 08/01/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728897
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729205
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729207
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770545
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 07/31/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729251
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 07/31/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729253
Principal investigator 1 Boehringer Ingelheim International GmbH $770.06 07/30/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220728961
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 07/28/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728793
Principal investigator 1 Boehringer Ingelheim International GmbH $5.22 07/28/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728795
Principal investigator 1 Boehringer Ingelheim International GmbH $174.90 07/28/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728903
Principal investigator 1 Boehringer Ingelheim International GmbH $119.88 07/28/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728905
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 07/28/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728907
Principal investigator 1 Boehringer Ingelheim International GmbH $48.85 07/28/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728909
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 07/28/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220728963
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 07/28/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729257
Principal investigator 1 Boehringer Ingelheim International GmbH $16,986.00 07/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729181
Principal investigator 1 Boehringer Ingelheim International GmbH $3,226.00 07/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729185
Principal investigator 1 Boehringer Ingelheim International GmbH $1,386.00 07/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729191
Principal investigator 1 Boehringer Ingelheim International GmbH $1,386.00 07/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729193
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 07/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729197
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 07/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729199
Principal investigator 1 Boehringer Ingelheim International GmbH $107.00 07/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729201
Principal investigator 1 Boehringer Ingelheim International GmbH $44.00 07/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729203
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $391.52 07/25/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220815069
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,025.00 07/09/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808234
Principal investigator 1 Boehringer Ingelheim International GmbH $3,226.00 07/07/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729183
Principal investigator 1 Boehringer Ingelheim International GmbH $2,018.00 07/07/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729187
Principal investigator 1 Boehringer Ingelheim International GmbH $2,018.00 07/07/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729189
Principal investigator 1 Boehringer Ingelheim International GmbH $1,118.00 07/07/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729195
Principal investigator 1 Madrigal Pharmaceuticals $2,252.88 07/04/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246583
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728775
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728777
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728779
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728781
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728783
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728787
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 07/01/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728871
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729213
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729215
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770543
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 06/30/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729171
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 06/30/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729173
Principal investigator 1 Boehringer Ingelheim International GmbH $125.10 06/25/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220728943
Principal investigator 1 Boehringer Ingelheim International GmbH $278.00 06/25/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220728945
Principal investigator 1 Boehringer Ingelheim International GmbH $90.35 06/25/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220728947
Principal investigator 1 Boehringer Ingelheim International GmbH $48.65 06/25/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220728949
Principal investigator 1 Boehringer Ingelheim International GmbH $243.25 06/25/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220728951
Principal investigator 1 Boehringer Ingelheim International GmbH $125.00 06/25/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220728953
Principal investigator 1 Boehringer Ingelheim International GmbH $152.90 06/25/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220728955
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 06/24/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728751
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 06/24/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728753
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 06/24/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220728957
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 06/24/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220728959
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 06/24/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729177
Principal investigator 1 Boehringer Ingelheim International GmbH $1.08 06/24/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729179
Principal investigator 1 Bausch Health US, LLC $2,428.16 06/05/2025 Non-covered Recipient Entity
IMPACT RESEARCH INSTITUTE 54723
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224841899
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,544.30 06/05/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808232
Principal investigator 1 Ipsen Bioscience Inc. $300.00 06/05/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176547131
Principal investigator 1 Ipsen Bioscience Inc. $1,150.00 06/05/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176547133
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728735
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728737
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728739
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728741
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728743
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728745
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 06/01/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728901
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729159
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729161
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 06/01/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770535
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 06/01/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770537
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 06/01/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770539
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220770541
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 05/30/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729167
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 05/30/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729169
Principal investigator 1 Ipsen Bioscience Inc. $1,250.00 05/28/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176547121
Principal investigator 1 Ipsen Bioscience Inc. $13,000.00 05/28/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176547123
Principal investigator 1 Ipsen Bioscience Inc. $1,300.00 05/28/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176547125
Principal investigator 1 Ipsen Bioscience Inc. $2,032.00 05/28/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176547127
Principal investigator 1 Ipsen Bioscience Inc. $2,500.00 05/28/2025 Non-covered Recipient Entity
Velocity Clinical Research
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176547129
Principal investigator 1 Madrigal Pharmaceuticals $2,252.88 05/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244674
Principal investigator 1 Boehringer Ingelheim International GmbH $16,259.00 05/27/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729151
Principal investigator 1 Boehringer Ingelheim International GmbH $58.30 05/27/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729175
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,445.00 05/27/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220800678
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 05/26/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192098710
Principal investigator 1 Madrigal Pharmaceuticals $2,644.52 05/15/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243853
Principal investigator 1 Boehringer Ingelheim International GmbH $695.00 05/09/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729135
Principal investigator 1 Boehringer Ingelheim International GmbH $85.00 05/09/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729137
Principal investigator 1 Boehringer Ingelheim International GmbH $626.00 05/09/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729139
Principal investigator 1 Boehringer Ingelheim International GmbH $764.00 05/09/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729141
Principal investigator 1 Boehringer Ingelheim International GmbH $518.00 05/09/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729143
Principal investigator 1 Boehringer Ingelheim International GmbH $800.00 05/09/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729145
Principal investigator 1 Boehringer Ingelheim International GmbH $1,045.00 05/09/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729147
Principal investigator 1 Boehringer Ingelheim International GmbH $245.00 05/09/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729149
Principal investigator 1 Boehringer Ingelheim International GmbH $2,748.00 05/09/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729153
Principal investigator 1 Bausch Health US, LLC $3,242.26 05/07/2025 Non-covered Recipient Entity
IMPACT RESEARCH INSTITUTE 54723
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224841894
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728723
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728725
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728727
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728729
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728731
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728733
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 05/01/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728869
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729155
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729157
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 04/30/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729163
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 04/30/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729165
Principal investigator 1 Madrigal Pharmaceuticals $14,190.12 04/28/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242823
Principal investigator 1 Boehringer Ingelheim International GmbH $4,217.00 04/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729099
Principal investigator 1 Boehringer Ingelheim International GmbH $58.00 04/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729101
Principal investigator 1 Boehringer Ingelheim International GmbH $61.00 04/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729103
Principal investigator 1 Boehringer Ingelheim International GmbH $1,118.00 04/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729105
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729107
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 04/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729109
Principal investigator 1 Boehringer Ingelheim International GmbH $135.00 04/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729111
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 04/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729113
Principal investigator 1 Boehringer Ingelheim International GmbH $2,641.00 04/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729115
Principal investigator 1 Boehringer Ingelheim International GmbH $3,774.00 04/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729117
Principal investigator 1 Boehringer Ingelheim International GmbH $3,226.00 04/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729119
Principal investigator 1 Boehringer Ingelheim International GmbH $1,118.00 04/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729121
Principal investigator 1 Boehringer Ingelheim International GmbH $1,386.00 04/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729123
Principal investigator 1 Boehringer Ingelheim International GmbH $1,118.00 04/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729125
Principal investigator 1 Boehringer Ingelheim International GmbH $16,986.00 04/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729127
Principal investigator 1 Boehringer Ingelheim International GmbH $452.00 04/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729129
Principal investigator 1 Boehringer Ingelheim International GmbH $44.00 04/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729131
Principal investigator 1 Boehringer Ingelheim International GmbH $107.00 04/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729133
Principal investigator 1 Boehringer Ingelheim International GmbH $657.00 04/23/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728747
Principal investigator 1 Boehringer Ingelheim International GmbH $10.44 04/23/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728749
Principal investigator 1 Boehringer Ingelheim International GmbH $16,259.00 04/11/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729089
Principal investigator 1 Boehringer Ingelheim International GmbH $3,774.00 04/11/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729091
Principal investigator 1 Boehringer Ingelheim International GmbH $16,259.00 04/11/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729093
Principal investigator 1 Boehringer Ingelheim International GmbH $3,774.00 04/11/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729095
Principal investigator 1 Boehringer Ingelheim International GmbH $2,641.00 04/11/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729097
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,491.80 04/11/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808230
Principal investigator 1 Bausch Health US, LLC $13,024.40 04/01/2025 Non-covered Recipient Entity
IMPACT RESEARCH INSTITUTE 54723
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224841903
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728711
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728713
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728715
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728717
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728719
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728721
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 04/01/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728865
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729085
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729087
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 03/31/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729059
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 03/31/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729061
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 03/25/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728861
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 03/25/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728863
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 03/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729077
Principal investigator 1 Boehringer Ingelheim International GmbH $305.35 03/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729079
Principal investigator 1 Boehringer Ingelheim International GmbH $8.10 03/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729081
Principal investigator 1 Boehringer Ingelheim International GmbH $29.20 03/25/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729083
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $17,066.70 03/24/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808228
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,120.00 03/12/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220800676
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,000.00 03/12/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808226
Principal investigator 1 Bausch Health US, LLC $2,428.16 03/11/2025 Non-covered Recipient Entity
IMPACT RESEARCH INSTITUTE 54723
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224841885
Principal investigator 1 Eli Lilly and Company $1,254.00 03/06/2025 Non-covered Recipient Entity
AUSTIN GASTROENTEROLOGY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187877767
Principal investigator 2 Madrigal Pharmaceuticals $5,343.17 03/06/2025 Non-covered Recipient Entity
IMPACT RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240392
Principal investigator 1 Bausch Health US, LLC $3,111.50 03/05/2025 Non-covered Recipient Entity
IMPACT RESEARCH INSTITUTE 54723
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224841888
Principal investigator 1 Boehringer Ingelheim International GmbH $3,774.00 03/03/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729063
Principal investigator 1 Boehringer Ingelheim International GmbH $2,641.00 03/03/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729065
Principal investigator 1 Boehringer Ingelheim International GmbH $3,226.00 03/03/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729067
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728691
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728693
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728695
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728697
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728699
Principal investigator 1 Boehringer Ingelheim International GmbH $49.88 03/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728701
Principal investigator 1 Boehringer Ingelheim International GmbH $43.00 03/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728703
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728705
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 03/01/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728867
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729047
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729049
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 02/28/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729055
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 02/28/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729057
Principal investigator 1 Madrigal Pharmaceuticals $8,000.00 02/27/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240051
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 02/25/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728707
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 02/25/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728855
Principal investigator 1 Boehringer Ingelheim International GmbH $1,058.50 02/25/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728857
Principal investigator 1 Boehringer Ingelheim International GmbH $10.00 02/25/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728859
Principal investigator 1 Boehringer Ingelheim International GmbH $209.88 02/25/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220728933
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 02/25/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220728935
Principal investigator 1 Boehringer Ingelheim International GmbH $730.00 02/25/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220728937
Principal investigator 1 Boehringer Ingelheim International GmbH $58.62 02/25/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220728939
Principal investigator 1 Boehringer Ingelheim International GmbH $6.00 02/25/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis No dispute reported 06/30/2026 1220728941
Principal investigator 1 GlaxoSmithKline, LLC. $4,000.00 02/21/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME No dispute reported 06/30/2026 1192098704
Principal investigator 1 Boehringer Ingelheim International GmbH $5,000.00 02/13/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728849
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 02/13/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728851
Principal investigator 1 Boehringer Ingelheim International GmbH $14,500.00 02/13/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728853
Principal investigator 1 Madrigal Pharmaceuticals $4,775.22 02/06/2025 Non-covered Recipient Entity
IMPACT RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239216
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728679
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728681
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728683
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728685
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728687
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728689
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 02/01/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728899
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729043
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729045
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,000.00 02/01/2025 Non-covered Recipient Entity
Velocity Clinical Research Durham
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220800674
Principal investigator 1 Bausch Health US, LLC $709.10 01/31/2025 Non-covered Recipient Entity
IMPACT RESEARCH INSTITUTE 54723
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224841881
Principal investigator 1 Boehringer Ingelheim International GmbH $35.00 01/31/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729051
Principal investigator 1 Boehringer Ingelheim International GmbH $42.00 01/31/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729053
Principal investigator 1 Boehringer Ingelheim International GmbH $139.86 01/27/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729069
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 01/27/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729071
Principal investigator 1 Boehringer Ingelheim International GmbH $2.16 01/27/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729073
Principal investigator 1 Boehringer Ingelheim International GmbH $23.36 01/27/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729075
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $17,775.00 01/17/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220808224
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $93,347.05 01/17/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH WACO
A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1214124592
Principal investigator 1 Boehringer Ingelheim International GmbH $4,217.00 01/15/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220728991
Principal investigator 1 Boehringer Ingelheim International GmbH $902.00 01/15/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220728993
Principal investigator 1 Boehringer Ingelheim International GmbH $3,451.00 01/15/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220728995
Principal investigator 1 Boehringer Ingelheim International GmbH $3,001.00 01/15/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220728997
Principal investigator 1 Boehringer Ingelheim International GmbH $979.00 01/15/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220728999
Principal investigator 1 Boehringer Ingelheim International GmbH $2,954.00 01/15/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729001
Principal investigator 1 Boehringer Ingelheim International GmbH $3,226.00 01/15/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729003
Principal investigator 1 Boehringer Ingelheim International GmbH $2,641.00 01/15/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729005
Principal investigator 1 Boehringer Ingelheim International GmbH $2,641.00 01/15/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729007
Principal investigator 1 Boehringer Ingelheim International GmbH $3,451.00 01/15/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729009
Principal investigator 1 Boehringer Ingelheim International GmbH $3,001.00 01/15/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729011
Principal investigator 1 Boehringer Ingelheim International GmbH $2,954.00 01/15/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729013
Principal investigator 1 Boehringer Ingelheim International GmbH $3,226.00 01/15/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729015
Principal investigator 1 Boehringer Ingelheim International GmbH $2,641.00 01/15/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729017
Principal investigator 1 Boehringer Ingelheim International GmbH $3,451.00 01/15/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729019
Principal investigator 1 Boehringer Ingelheim International GmbH $3,001.00 01/15/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729021
Principal investigator 1 Boehringer Ingelheim International GmbH $2,954.00 01/15/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729023
Principal investigator 1 Boehringer Ingelheim International GmbH $3,226.00 01/15/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729025
Principal investigator 1 Boehringer Ingelheim International GmbH $2,641.00 01/15/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729027
Principal investigator 1 Boehringer Ingelheim International GmbH $2,641.00 01/15/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729029
Principal investigator 1 Boehringer Ingelheim International GmbH $3,451.00 01/15/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729031
Principal investigator 1 Boehringer Ingelheim International GmbH $979.00 01/15/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729033
Principal investigator 1 Boehringer Ingelheim International GmbH $3,001.00 01/15/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729035
Principal investigator 1 Boehringer Ingelheim International GmbH $2,954.00 01/15/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729037
Principal investigator 1 Bausch Health US, LLC $2,428.16 01/07/2025 Non-covered Recipient Entity
IMPACT RESEARCH INSTITUTE 54723
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1224841891
Principal investigator 1 Eli Lilly and Company $60,652.00 01/07/2025 Non-covered Recipient Entity
AUSTIN GASTROENTEROLOGY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187880869
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728669
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728671
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728673
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728675
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728677
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Impact Research Institute
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220728709
Principal investigator 1 Boehringer Ingelheim International GmbH $55.00 01/01/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728841
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728843
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 01/01/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728845
Principal investigator 1 Boehringer Ingelheim International GmbH $28.00 01/01/2025 Non-covered Recipient Entity
Impact Research Institute
A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis No dispute reported 06/30/2026 1220728847
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729039
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Impact Research Institute
Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) No dispute reported 06/30/2026 1220729041
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $327,327.38 01/01/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH WACO
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1214124304